Resistin is associated with overall survival in non‑small cell lung cancer patients during nivolumab treatment

• A. Bonaventura ^[1] ; F. Grossi ^[2] ; F. Carbone ^[1] ; A. Vecchié ^[1] ; S. Minetti ^[1] ; N. Bardi ^[1] ; E. Elia ^[1] ; A. M. Ansaldo ^[1] ; D. Ferrara ^[1] ; E. Rijavec ^[3] ; M. G. Dal Bello ^[3] ; G. Rossi ^[3] ; F. Biello ^[4] ; M. Tagliamento ^[3] ; A. Alama ^[3] ; S. Coco ^[3] ; P. Spallarossa ^[5] ; F. Dallegri ^[1] ; C. Genova ^[6] ; F. Montecucco ^[6]
  1. [1] University of Genoa

     University of Genoa

     Genoa, Italia

     
  2. [2] Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Medical Oncology, Milan, Italy
  3. [3] IRCCS Ospedale Policlinico San Martino, UOS Tumori Polmonari, Largo R. Benzi 10, 16132 Genoa, Italy
  4. [4] Azienda Ospedaliero-Universitaria Maggiore Della Carità, Novara, Italy
  5. [5] Cardiovascular Diseases Unit, IRCCS Ospedale Policlinico San Martino-Italian Cardiovascular Network, Genoa, Italy
  6. [6] IRCCS Ospedale Policlinico San Martino Genova-Italian Cardiovascular Network, Largo R. Benzi 10, 16132 Genoa, Italy

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 9, 2020, págs. 1603-1610
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose Since the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS.

    Methods/patients From a cohort of 78 patients with advanced NSCLC enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 43 patients have been considered for this sub-analysis because of the availability of samples.

    Before and during nivolumab administration, clinical information and blood samples were collected and resistin, matrix metalloproteinase (MMP)-8, MMP-9, and myeloperoxidase were evaluated by enzyme-linked immunosorbent assay (ELISA).

    Results Median age was 71 with a prevalence of males and former smokers. Median resistin levels presented a peak at cycle 2 and then dropped down until the last cycle. Resistin correlated with all neutrophil degranulation products at cycle 1 (except for MMP-9) and at cycle 2 as well as with white blood cells and neutrophils. By a ROC curve analysis, a resistin value at cycle 2 of 19 ng/mL was tested as the best cut-off point for OS. Kaplan–Meier analysis demonstrated that patients above the resistin cut-off experienced a reduced OS (median OS 242.5 vs. 470 days, p = 0.0073), as confirmed by Cox proportional hazards regression analysis.

    Conclusions Resistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC.